Forcura, a healthcare workflow management company, announces a strategic ecosystem partnership with HealthRev Partners, a prominent provider of revenue cycle management services for the home health, hospice, and palliative care sectors. This collaboration focuses on enhancing the referral process for agencies operating in these critical healthcare segments. Through this innovative partnership, agencies will benefit from a seamless and integrated approach to managing referrals, ensur

Inogen, a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies. The study sourced data from the French national healthcare system database, the Système National des Données de San

ARUP Laboratories is backing a federal lawsuit filed by the American Clinical Laboratory Association (ACLA) challenging the FDA's final rule to regulate laboratory-developed tests (LDTs) as medical devices. The lawsuit states that the FDA does not have legal authority over medical testing services from Congress and asserts that regulating these services is unreasonable. ARUP, one of the nation's four largest reference laboratories, with hospital and health system clients in

Head for the Cure, the Musella Foundation For Brain Tumor Research & Information, and Cancer Commons today announced the launch of the Brain Cancer Support and Solutions Alliance to provide support, education, and guidance to brain cancer patients and their caregivers. Brain tumors present unique challenges, demanding specialized care from diagnosis through treatment. With a shared commitment to addressing these challenges, the Brain Cancer Support and Solutions Alliance will le

Inspira™ Technologies OXY B.H.N. a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the Company's business targets, distribution agreements and next steps in a conference call to be held at 9:00am Eastern Time on Thursday, June 20, 2024. This follows the significant milestone of receiving FDA clearance for the INSPIRA™ ART100 system, as announced on May 28, 2024. Event Detai

Stout, a leading global advisory firm, is pleased to announce the acquisition of HealthCare Appraisers, Inc., a premier provider of healthcare valuation and consulting services. HealthCare Appraisers has been a market leader in healthcare valuation for over two decades and brings unparalleled expertise and a proven track record of delivering exceptional service to its clients. This strategic move underscores Stout's commitment to expanding its healthcare valuation capabilities and further

The Society for Simulation in Healthcare (SSH), in collaboration with the Society for Simulation in Europe (SESAM), is proud to announce the release of the "Global Consensus Statement on Simulation-Based Practice in Healthcare." This groundbreaking statement, developed also in collaboration with representatives from 50 simulation societies across 67 countries, underscores the transformative power of simulation in healthcare education, training, and practice. The

Luma Health, creator of the market-leading Patient Success Platform™, has been selected by Modern Healthcare as one of the 2024 Best Places to Work in Healthcare. The award identifies and recognizes outstanding employers in the healthcare industry nationwide, and combines an assessment of a company's practices and policies with independent employee feedback. Luma Health's commitment to transforming the patient healthcare journey has not only attracted top talent in the

Aliter Capital has confirmed the rebranding of the integrated healthcare technology platform business in its Aliter Capital II fund. Previously known as Halcyon, the group is now Athera Healthcare, with a focus on combining the best technologies and people, to empower healthcare organisations to drive progress, improve operational efficiency and advance patient care.  Aliter continues to work closely with Athera Healthcare’s management team to support further or

AbbVie announced today that it has completed its acquisition of Landos Biopharma, With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowe